{"id":"W4406679883","doi":"10.1038/s41591-024-03415-7","title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Breast cancer; Internal medicine; Oncology; Epirubicin; Placebo; Chemotherapy; Population; Docetaxel; Neoadjuvant therapy; Cyclophosphamide; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003511406,0.0002593938,0.0006813475,0.0001222991,0.00007287813,0.000008924475,0.000123355,0.0003237047,0.00006640742],"category_scores_gemma":[0.000196524,0.0001809043,0.00007938527,0.0002281197,0.0003016587,0.000003743399,0.0000545651,0.0003727271,5.706479e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005379641,"about_ca_system_score_gemma":0.0001006848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003540813,"about_ca_topic_score_gemma":0.0008520967,"domain_scores_codex":[0.9987001,0.0001556254,0.0002946062,0.0004443347,0.0001636208,0.0002416993],"domain_scores_gemma":[0.9993699,0.00009429926,0.0001253291,0.0002663868,0.00008261245,0.0000615048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9426364,0.0003437925,0.009702751,0.00005721725,0.0008294811,0.00001647792,0.000331112,0.00000295444,0.001788766,0.0003198824,0.00590935,0.03806178],"study_design_scores_gemma":[0.9494244,0.0003392477,0.03848188,0.0001420134,0.0002217999,0.000008008855,0.00006010662,0.00001554622,0.002393328,0.0001913463,0.008551221,0.0001710334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971428,0.01571646,0.00007105329,0.0105826,0.0006790753,0.0008638462,0.0001086159,0.00001906275,0.0005312554],"genre_scores_gemma":[0.987364,0.008916321,0.00006119733,0.00158685,0.0008213785,0.0002365214,0.00006930036,0.0000193756,0.0009250568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03789075,"threshold_uncertainty_score":0.7377064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003714202626114731,"score_gpt":0.3019830404053858,"score_spread":0.298268837779271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}